AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06471517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory feedback
Description: Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
Study NCT05549453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexstim SNBT use
Description: Active device use
Study NCT05670197 — intervention group
Intervention type: OTHER
Intervention: No intervention. Participants will take part in a qualitative interview
Description: No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
Study NCT06184724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Package for CGA
Description: The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
Study NCT06184724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Clinical Care
Description: Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
Study NCT06197711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISMA
Description: PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions.
Study NCT04609566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
Study NCT04609566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg given intravenously every 3 weeks
Study NCT04530695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Periodontal treatment by scaling and root planing (SRP), deep cleaning
Study NCT06517927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical and radiographic dental examination
Description: complete clinical oral examination + intra-oral and panoramic x-rays
Study NCT06517927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and radiographic dental examination
Description: complete clinical oral examination + intra-oral and panoramic x-rays
Study NCT05198167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids
Description: Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
Study NCT05198167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Description: Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
Study NCT06054880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigotindisulfonate sodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Study NCT06054880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection 0.9%
Description: Placebo
Study NCT06054880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection 0.9%
Description: Placebo
Study NCT06157827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-024 for Injection
Description: Initial dose-MTD; Q3W; intravenous infusion
Study NCT05096286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethos Therapy
Description: FDA-approved treatment planning system
Study NCT04791813 — intervention group
Intervention type: OTHER
Intervention: Alginate impressions , Photographic data and panoramic radiographs .
Description: Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
Study NCT06000176 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: diagnostic test OCTA macula and ONH
Study NCT05354804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Troponin I (Siemens VTli) 0/1 hour algorithm
Description: Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
Study NCT05354804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm
Description: Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
Study NCT06459141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
Study NCT05809739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE Hydro
Description: 3 sessions of injections (J0, J14 and J28)
Study NCT06500520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resisted Exercise group
Description: The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.
Study NCT06500520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise group
Description: The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
Study NCT04843813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Participants will consume daily soft gels containing the lutein supplement.
Study NCT04843813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume daily soft gels containing the safflower oil.
Study NCT06448026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV
Study NCT06448026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV
Study NCT06641089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Sonelokimab
Study NCT06641089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06641089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Active comparator
Study NCT05685238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8
Description: Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
Study NCT05882266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant Omega
Description: A commercial plant-based omega-3 beverage consumed once daily during breakfast
Study NCT05882266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary therapy only
Description: Standard dietary therapy
Study NCT06093191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Study NCT06093191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
Study NCT06093191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral ciprofloxacin placebo
Description: Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
Study NCT06093191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ciprofloxacin placebo
Description: Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
Study NCT05170568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD7 chimeric antigen receptor
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
Study NCT06157827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study NCT06157827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study NCT06157827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab injection
Description: Initial dose; Q3W; intravenous infusion
Study NCT06157827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study NCT06244199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T2CR Intervention
Description: The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
Study NCT06244199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
Study NCT05075577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Daily oral dose of enzalutamide
Study NCT05075577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide
Study NCT04980872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
Study NCT04368130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIGNAL
Description: SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly.
Study NCT05822999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WELT-IP
Description: WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
Study NCT05822999 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
Study NCT05916638 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: blood sample collection
Study NCT06665568 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal ketamine hydrochloride
Description: Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
Study NCT06670924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running suture for vesico-urethral anastomosis in open radical prostatectomy
Description: The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.
Study NCT06670924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interrupted suture for vesico-urethral anastomosis in open radical prostatectomy
Description: The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
Study NCT06673407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exposure for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears.
Study NCT06673407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion.
Study NCT06673407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
Study NCT06673407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
Study NCT06672861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)
Description: To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
Study NCT06671236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
Description: Regulatory T cell therapy, intrathecal injection
Study NCT06517810 — intervention group
Intervention type: DEVICE
Intervention: QUELIMMUNE (SCD-PED)
Description: QUELIMMUNE device used as part of clinical practice.
Study NCT05105958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tideglusib
Description: 1000 mg/day per os
Study NCT05105958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: 1000 mg/day per os
Study NCT05994157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD38-SADA:177Lu-DOTA Complex
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
Study NCT06300281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise
Description: A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
Study NCT06300281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
Study NCT04457310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 1 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study NCT04457310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 4 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study NCT04457310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 15 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study NCT04457310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 25 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study NCT04457310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study NCT04529031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder Focused Positive Psychiatry
Description: The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices